BofA lowered the firm’s price target on Avidity Biosciences (RNA) to $48 from $51 and keeps a Buy rating on the shares. The firm rolled the quarter, updated for Q4 results, cash and share count, and adjusted operating expense estimates based on management commentary.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Avidity Biosciences initiated with an Outperform at Scotiabank
- Avidity Biosciences: Positioned for Transformative Growth with Promising Pipeline and Strategic Launch Preparations
- Avidity Biosciences Advances RNA Therapeutics for Rare Diseases
- Positive Outlook for Avidity Biosciences Driven by Promising Pipeline Developments and Strong Financial Position
Questions or Comments about the article? Write to editor@tipranks.com